Vutrisiran Fast-Tracked for Polyneuropathy of hATTR Amyloidosis
The FDA has granted Fast Track designation to vutrisiran (Alnylam) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Cardiovascular Diseases
Tea Drinking Linked to Reduced Risk for Atherosclerotic CVD
Risks for atherosclerotic CVD incidence and mortality, all-cause mortality lower in habitual tea drinkers.
Glass Fragment Prompts Recall of Immunosuppressive Agent
Par is recalling 1 lot of Mycophenolate Mofetil for Injection (lot# AD812; expiration date: 9/2020) following the discovery of a glass fragment within a reconstituted vial.
No Clear Benefit for Rivaroxaban After Hospital Discharge
The researchers found that a composite outcome of symptomatic venous thromboembolism or death due to venous thromboembolism occurred in 0.83% of patients in the rivaroxaban group and in 1.10% in the placebo group (hazard ratio, 0.76; 95% confidence interval, 0.52 to 1.09; P=0.14).
